Notes
to Consolidated Financial Statements
May
31, 2016 and 2015
Unaudited
Note
1 Basis of Presentation
The
accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the instructions
to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Certain
information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles
generally accepted in the United States of America have been condensed or omitted, pursuant to the rules and regulations of the
SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive
presentation of financial position, results of operations, or cash flows. It is our opinion, however, that the accompanying unaudited
interim consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary
for a fair presentation of the financial position, operating results and cash flows for the periods presented.
The
accompanying unaudited interim consolidated financial statements should be read in conjunction with our Annual Report on Form
10-K for the year ended November 30, 2015 as filed with the SEC, which contains the audited financial statements and notes thereto,
together with Management’s Discussion and Analysis, for the years ended November 30, 2015 and 2014. The financial information
as of May 31, 2016 is derived from the audited financial statements presented in our Annual Report on Form 10-K for the year ended
November 30, 2015. The interim results for the three and six months ended May 31, 2016 are not necessarily indicative of the results
to be expected for the year ending November 30, 2016 or for any future interim periods.
Fair
Value of Financial Instruments
BioPower
evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as
embedded derivatives. The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued
expenses and loans . The carrying amount of these financial instruments approximates fair value due either to length
of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.
For
derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its
fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity,
is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current
or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of
the balance sheet date.
Financial
assets and liabilities recorded at fair value in our balance sheets are categorized based upon a fair value hierarchy established
by GAAP, which prioritizes the inputs used to measure fair value into the following levels:
Fair
Value of Financial Instruments
Level
1— Quoted market prices in active markets for identical assets or liabilities at the measurement date.
Level
2— Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and
liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data.
Level
3— Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing
assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the
instruments.
A
financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant
to the fair value measurement.
Financial
assets and liabilities measured at fair value on a recurring basis are summarized below for the quarter ended November 30, 2015
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities -available for sale
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative Financial Instruments
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
60,356
|
|
|
$
|
60,356
|
|
BioPower
Operations Corporation and Subsidiaries
Notes
to Consolidated Financial Statements
May
31, 2016 and 2015
Unaudited
Financial
assets and liabilities measured at fair value on a recurring basis are summarized below for the quarter ended May 31, 2016
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Securities -available for sale
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative Financial Instruments
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
81,739
|
|
|
$
|
81,739
|
|
The
following table presents details of the Company’s level 3 derivative liabilities as of May 31, 2016 and November 30, 2015:
|
|
Amount
|
|
Balance November 30, 2015
|
|
$
|
60,356
|
|
Debt discount originated from derivative liabilities
|
|
|
70,711
|
|
Change in fair market value of derivative liabilities
|
|
|
(49,328
|
)
|
Balance May 31, 2016
|
|
$
|
81,739
|
|
Revenue
Recognition Policy
The
Company recognizes revenues from construction contracts on the percentage-of-completion method, measured by the percentage of
direct labor and material costs to date to estimated total direct labor and material costs for each contract. This method is used
because management considers total cost to be the best available measure of progress on the contracts. Because of the inherent
uncertainties in estimating costs, it is at least reasonably possible that the estimates used will change in the near term.
Contract
costs include all direct labor and material cost and those indirect costs related to contract performance. General and administrative
costs are charged to expense as incurred. Provisions for estimated losses on uncompleted contracts are made in the period in which
such losses are determined. Changes in job performance, job conditions and estimated profitability may result in revisions to
cost and income, which are recognized in the period in which the revisions are determined.
The
asset, costs and estimated earnings in excess of billings on uncompleted contracts represents revenues recognized in excess of
amounts billed. The liability, billings in excess of costs and estimated earnings, represents billing in excess of revenues recognized.
Revenues
generated from services and consulting agreements are recognized when the services have been performed, all significant contractual
obligations have been satisfied and collection of the resulting fees is reasonably assured.
Note
2 Going Concern
As
reflected in the accompanying consolidated financial statements, the Company had a net loss of $1,340,517 and net cash used in
operations of $341,642 for the six months ended May 31, 2016. Additionally, the Company had a working capital deficit of $1,740,817and
a stockholders’ deficit of $3,887,621at May 31, 2016. These factors raise substantial doubt about the Company’s ability
to continue as a going concern.
The
ability of the Company to continue as a going concern is dependent on Management’s plans, which include funding of waste
to energy projects, implementation of waste remediation projects, further implementation of its business plan and continuing to
raise funds through debt and/or equity financings. The Company will likely rely upon debt and/or equity financing in order to
ensure the continuing existence of the business.
The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization
of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any
adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should
the Company be unable to continue as a going concern.
Note
3 Equipment
At
May 31, 2016 and November 30, 2015, equipment consists of the following:
|
|
2016
|
|
|
2015
|
|
|
Estimated Useful Life
|
Computer Equipment
|
|
$
|
36,800
|
|
|
$
|
36,800
|
|
|
5 years
|
Less: Accumulated depreciation
|
|
|
(28,514
|
)
|
|
|
(25,924
|
)
|
|
|
Equipment, net
|
|
$
|
8,286
|
|
|
$
|
10,876
|
|
|
|
Note
4. Notes Payable and Convertible Debt
|
|
|
Balance
|
|
|
Interest Rate
|
|
|
Maturity
|
|
Balance
– November 30, 2015
|
|
|
$
|
|
132,500
|
|
|
|
Various
|
|
|
|
Various
|
|
Borrowings
|
|
|
|
|
5,000
|
|
|
|
8%
|
|
|
|
June
30, 2016
|
|
Balance – May
31, 2016
|
|
|
$
|
|
137,500
|
|
|
|
|
|
|
|
|
|
In
January, 2016 a third party investor advanced $5,000 unsecured at 8% interest , which was due on June 30, 2016 and paid in
full as of the due date.
BioPower
Operations Corporation and Subsidiaries
Notes
to Consolidated Financial Statements
May
31, 2016 and 2015
Unaudited
Convertible
debt consists of the following:
|
|
Balance
|
|
|
Interest Rate
|
|
|
Maturity
|
|
Conversion Price
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance – November 30, 2015
|
|
$
|
189,366
|
|
|
|
8
|
%
|
|
In Default
|
|
|
Various
|
|
Reclass non related to related
|
|
|
(74,448
|
)
|
|
|
8
|
%
|
|
December 30, 2015
|
|
|
0.15
|
|
Reclass non related to related
|
|
|
(50,000
|
)
|
|
|
8
|
%
|
|
December 30, 2016
|
|
|
0.15
|
|
Reclass debt discount to related
|
|
|
78,113
|
|
|
|
|
|
|
|
|
|
|
|
Borrowings
|
|
|
25,000
|
|
|
|
8
|
%
|
|
May 23, 2018
|
|
|
0.10
|
|
Debt discount on derivative
|
|
|
(23,579
|
)
|
|
|
|
|
|
|
|
|
|
|
Debt discount amortization
|
|
|
258
|
|
|
|
|
|
|
|
|
|
|
|
Balance – May 31, 2016
|
|
$
|
144,710
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current portion
|
|
|
(143,031
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long term portion
|
|
$
|
1,679
|
|
|
|
|
|
|
|
|
|
|
|
In February, 2016 a third party investor’s
convertible debt totaling $74,448, net of related debt discount of $40,470, was reclassified as related party because during the
period, as the investor’s ownership of common stock increased to greater than 10%, which, due to materiality, required his
transactions to be reclassified as “related party transactions.”
On
March 10, 2016, a third party investor’s convertible debt totaling $50,000, net of related debt discount of $37,643, was
reclassified as a related party transaction due to the investor being hired as the Company’s Chief Operating Officer and
Director of Business Development.
On
May 23, 2016, the Company entered into convertible debt agreements with a third party investor totaling $25,000 at 8% interest,
due on May 23, 2018. The debt is convertible into common shares of stock at a conversion price of $.10 per share. On this date
the Company recorded a debt discount of $23,579 from the initial valuation of the derivative liability of $23,579 and resulting
in no initial gain or loss on the derivative liability based on the Black Sholes pricing model. The fair value of the derivative
liability at May 31, 2016 is $23,579. The note is shown net of a derivative debt discount of $23,321 at May 31, 2016.
Accrued
interest on notes payable and convertible debt at May 31, 2016 and November 30, 2015 amounted to $32,611 and $23,316, respectively,
which is included as a component of accounts payable and accrued expenses.
Interest
expense on notes payable and convertible debt with third parties amounted to $6,496 and $5,330 for the three months ended May
31, 2016 and 2015, respectively.
Note
5. Related Party Transactions
Notes
payable to related parties consists of the following:
|
|
Balance
|
|
|
Interest Rate
|
|
|
Maturity
|
Balance – November 30, 2015
|
|
$
|
525
|
|
|
|
0
|
%
|
|
On Demand
|
Borrowings
|
|
|
194,939
|
|
|
|
12
|
%
|
|
May 30, 2016
|
Reclass accrued compensation
|
|
|
874,000
|
|
|
|
4
|
%
|
|
December 1, 2017
|
Reclass accrued compensation
|
|
|
669,582
|
|
|
|
4
|
%
|
|
December 1, 2017
|
Reclass accrued compensation
|
|
|
150,000
|
|
|
|
4
|
%
|
|
December 1, 2017
|
Reclass accrued compensation
|
|
|
120,000
|
|
|
|
4
|
%
|
|
December 1, 2017
|
Reclass accrued compensation
|
|
|
120,000
|
|
|
|
4
|
%
|
|
December 1, 2017
|
Reclass accrued compensation
|
|
|
120,000
|
|
|
|
4
|
%
|
|
December 1, 2017
|
Balance – May 31, 2016
|
|
$
|
2,249,046
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current portion
|
|
|
(195,464
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long term portion
|
|
$
|
2,053,582
|
|
|
|
|
|
|
|
BioPower
Operations Corporation and Subsidiaries
Notes
to Consolidated Financial Statements
May
31, 2016 and 2015
Unaudited
In
April, 2016 the Chief Operating Officer made an advance of $194,939 to a subsidiary of the Company, bearing interest at 12% which
is due May 30, 2016. The $194,939 non-convertible advance included an additional $15,000 payment as Profit Participation for work
rendered. The agreement included a provision where the Company agreed that in the event that the Investor had not been repaid
within 75 days from date of delivery of Equipment then Investor shall receive a penalty of 3,000,000 shares of BioPower Common
Stock in consideration for the delay in payment. The Investor was repaid in full on June 30, 2016.
On
May 27, 2016 the Chief Executive Officer agreed to reduce his accrued compensation by $206,250 as a contribution to additional
paid in capital. He also agreed to reclassify $874,000 in accrued compensation to long term debt upon the issuance of a non-convertible
4% interest bearing note with a maturity date of December 1, 2017. The compensation included was accrued during the period from
January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject
to a cap of 20% of operating net cash flow in any given period. If bonuses are paid accrued compensation will be paid with an
amount decided by the Board.
On
May 27, 2016 the Director of Strategy agreed to reduce her accrued compensation by $206,250 as a contribution to additional paid
in capital. She also agreed to reclassify $669,582 in accrued compensation to long term debt upon the issuance of a non-convertible
4% interest bearing note with a maturity date of December 1, 2017. The compensation included was accrued during the period from
January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject
to a cap of 20% of operating net cash flow in any given period. If bonuses are paid accrued compensation will be paid with an
amount decided by the Board.
On
May 27, 2016 the Chief Executive Officer of G3P agreed to reduce his accrued compensation by $243,750 as a contribution to additional
paid in capital. He also agreed to reclassify $150,000 in accrued compensation to long term debt upon the issuance of a non-convertible
4% interest bearing note with a maturity date of December 1, 2017. The compensation included was accrued during the period from
January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject
to a cap of 20% of operating net cash flow in any given period. If bonuses are paid accrued compensation will be paid with an
amount decided by the Board.
On
May 27, 2016 the Senior Vice President of G3P agreed to reduce his accrued compensation by $162,500 as a contribution to additional
paid in capital. He also agreed to reclassify $120,000 in accrued compensation to long term debt upon the issuance of a non-convertible
4% interest bearing note with a maturity date of December 1, 2017. The compensation included was accrued during the period from
January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject
to a cap of 20% of operating net cash flow in any given period. If bonuses are paid accrued compensation will be paid with an
amount decided by the Board.
On
May 27, 2016 the Chief Operating Officer of G3P agreed to reclassify $120,000 in accrued compensation to long term debt upon the
issuance of a non-convertible 4% interest bearing note with a maturity date of December 1, 2017. The compensation included was
accrued during the period from January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income
only and is further subject to a cap of 20% of operating net cash flow in any given period. If bonuses are paid accrued compensation
will be paid with an amount decided by the Board.
On
May 27, 2016 the Chief Administrative Officer of G3P agreed to reclassify $120,000 in accrued compensation to long term debt upon
the issuance of a non-convertible 4% interest bearing note with a maturity date of December 1, 2017. The compensation included
was accrued during the period from January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future
income only and is further subject to a cap of 20% of operating net cash flow in any given period. If bonuses are paid accrued
compensation will be paid with an amount decided by the Board.
BioPower
Operations Corporation and Subsidiaries
Notes
to Consolidated Financial Statements
May
31, 2016 and 2015
Unaudited
Convertible
debt to related parties consists of the following:
|
|
|
Balance
|
|
|
|
Interest
Rate
|
|
|
|
Maturity
|
|
|
|
Conversion
Price
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance – November 30, 2015
|
|
$
|
44,394
|
|
|
|
8
|
%
|
|
|
December
30, 2015
|
|
|
|
0.15
|
|
Reclass non related to related
|
|
|
74,448
|
|
|
|
8
|
%
|
|
|
December
30, 2015
|
|
|
|
0.15
|
|
Reclass non related to related
|
|
|
50,000
|
|
|
|
8
|
%
|
|
|
December
30, 2016
|
|
|
|
0.15
|
|
Reclass debt discount to related
|
|
|
(78,113
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Borrowings
|
|
|
25,000
|
|
|
|
8
|
%
|
|
|
June
15, 2016
|
|
|
|
0.15
|
|
Debt discount on convertible debt
|
|
|
(8333
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable settlement
|
|
|
16,500
|
|
|
|
8
|
%
|
|
|
June
17, 2016
|
|
|
|
0.15
|
|
Borrowings
|
|
|
100,000
|
|
|
|
8
|
%
|
|
|
March
2, 2018
|
|
|
|
0.15
|
|
Borrowings
|
|
|
50,000
|
|
|
|
8
|
%
|
|
|
May
18, 2018
|
|
|
|
0.10
|
|
Debt discount on derivative
|
|
|
(47,132
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt discount amortization
|
|
|
(71,960
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance – May 31, 2016
|
|
$
|
298,724
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current portion
|
|
|
(195,017
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long term portion
|
|
$
|
103,707
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On
December 15, 2015 a related party investor advanced $25,000 due on or before June 15, 2016. Pursuant to the agreement, the investor
is allowed to convert 100% of the debt at a share price of $0.15. The company accounted for the conversion of loan in accordance
with ASC 470, “Debt with Conversion and Other Options”. The loan was deemed to have a beneficial conversion feature
because the fair value of the stock exceeded the effective conversion price embedded in the loan on the commitment date. Accordingly,
the Company recorded the value of the beneficial conversion feature, which was determined to be $8,333 as a discount to the loan
and a corresponding increase to additional paid in capital.
On
February 18, 2016 a related party investor settled $16,500 in accounts payable for the Company in exchange for debt du e
on or before June 17, 2016. Pursuant to the agreement, the investor is allowed to convert 100% of the debt at a share price of
$0.15. The company accounted for the conversion of the debit in accordance with ASC 470, “Debt with Conversion and Other
Options”. The fair market value of the shares on February 18, 2016 was $0.10 per share and accordingly deemed to have no
Beneficial Conversion Factor.
In
March, 2016 the Chief Operating Officer made a loan of $100,000, bearing interest at 8% due on or before March 2, 2018. Pursuant
to the agreement, the investor is allowed to convert 100% of the debt on the maturity date at a share price of $0.15. The company
accounted for the conversion of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The
fair market value of the shares on March 2, 2016 was $0.10 per share and accordingly deemed to have no Beneficial Conversion Factor.
On May 18, 2016 the Officer loaned an additional $50,000 with conversion rights at $0.10 per share. Therefore, effective May 18,
2016, $50,000 of the officers’ note payable had conversion rights of $0.10 per share. The company accounted for the conversion
of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The fair market value of the shares
on May 18, 2016 was $0.10 per share and accordingly deemed to have no Beneficial Conversion Factor. On May 23, 2016, a third party
investor loaned the company $25,000 with conversion rights at $0.10 per share. Therefore, effective May 23, 2016, an additional
$25,000 of the officers’ $100,000 note payable had conversion rights of $0.10 per share. The company accounted for the conversion
of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The fair market value of the shares
on May 18, 2016 was $0.10 per share and accordingly deemed to have no Beneficial Conversion Factor.
In
May, 2016 the Chief Operating Officer made a loan of $50,000, bearing interest at 8% due on or before May 18, 2018. Pursuant to
the agreement, the investor is allowed to convert 100% of the debt at a share price of $0.10 . The loan includes a provision
for matching future conversion rights with any new loans made by the Company with the exception of a Right of First Refusal. In
addition, if an equity transaction is done at a price below $0.10 then the conversion price will adjust to such price. The
company accounted for the conversion of loan in accordance with ASC 470, “Debt with Conversion and Other Options”.
The fair market value of the shares on May 18, 2016 was $0.10 per share and accordingly deemed to have no Beneficial Conversion
Factor.
Accrued
interest on related party notes payable and convertible debt at May 31, 2016 and November 30, 2015, amounted to $19,101 and $4,250,
respectively and is a component of accounts payable and accrued expenses – related parties.
Interest
expense on notes payable and convertible debt with related parties amounted to $8,881 and $2,747 for the three months ended May
31, 2016 and 2015, respectively.
BioPower
Operations Corporation and Subsidiaries
Notes
to Consolidated Financial Statements
May
31, 2016 and 2015
Unaudited
The
Company has separated accounts payable and accrued expenses on the balance sheet to reflect amounts due to related parties primarily
consisting of officer compensation, health insurance, interest on notes and reimbursable expenses to officers for travel, meals
and entertainment, vehicle and other related business expenses.
Note
6. Derivative Liabilities
On
July 23, 2015, the Company entered into a convertible loan agreement with an investor. The Company received a total of $50,000
which bears interest at 8% per annum and is due on December 30, 2016. Interest shall accrue from the advancement date and shall
be payable on December 30, 2016. Any portion of the loan and unpaid interest are convertible at any time at the option of the
lender into shares of common stock of the Company at a conversion price of $0.15 per share. If an equity transaction occurs at
a price below $0.15, then the conversion price will adjust to such price.
On
this date of issuance, the Company recorded a debt discount in the amount of $50,000 in connection with the initial valuation
of the derivative liability of the note to be amortized utilizing the effective interest method of accretion over the term of
the note. Further, the Company recognized a derivative liability of $111,074 and initial loss on derivative liability of $61,074
based on the Black Scholes pricing model. As of May 31, 2016, $29,752 of the debt discount has been amortized. The fair
value of the derivative liability at May 31, 2016 is $11,046 resulting in a gain on the change in fair value of the derivative
of $49,310. The Note is shown net of a derivative debt discount of $20,247 at May 31, 2016.
Since
equity classification is not available for the conversion feature, we were required to bifurcate the embedded conversion feature
and carry it as a derivative liability, at fair value. Derivative financial instrument is carried initially and subsequently at
its fair values.
We
estimated the fair value of the derivative on the inception date, and subsequently, using the Black-Scholes valuation technique,
adjusted for the effect of dilution, because that technique embodies all of the assumptions (including, volatility, expected terms,
and risk free rates) that are necessary to fair value complex derivate instruments.
As
a result of the application of ASC No. 815 in period ended May 31, 2016 the fair value of the conversion feature is summarized
as follows:
|
|
Amount
|
|
Balance November 30, 2015
|
|
$
|
60,356
|
|
Change in fair market value of derivative liabilities
|
|
|
(49,310
|
)
|
Balance May 31, 2016
|
|
$
|
11,046
|
|
The
fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following
management assumptions as of May 31, 2016 and commitment date:
|
|
Commitment Date
|
|
|
May 31, 2016
|
|
Expected dividends
|
|
|
-
|
|
|
|
-
|
|
Expected volatility
|
|
|
296.84
|
%
|
|
|
153.55
|
%
|
Expect term
|
|
|
1.44
|
|
|
|
.58
|
|
Risk free interest rate
|
|
|
0.33
|
%
|
|
|
0.68
|
%
|
On
May 18, 2016, the Company entered into a convertible loan agreement with a related party investor. The Company received a total
of $50,000 which bears interest at 8% per annum and is due on May 18, 2018. Interest shall accrue from the advancement date and
shall be payable on May 18, 2018. Any portion of the loan and unpaid interest are convertible at any time at the option of the
lender into shares of common stock of the Company at a conversion price of $0.10 per share. If an equity transaction occurs at
a price below $0.10, then the conversion price will adjust to such price.
On
this date of issuance, the Company recorded a debt discount in the amount of $47,132 in connection with the initial valuation
of the derivative liability of the note to be amortized utilizing the effective interest method of accretion over the term of
the note. Further, the Company recognized a derivative liability of $47,132 resulting in no initial gain or loss on the derivative
liability based on the Black Scholes pricing model. As of May 31, 2016, $839 of the debt discount has been amortized. The fair
value of the derivative liability at May 31, 2016 is $47,114 resulting in a gain on the change in fair value of the derivative
of $18. The Note is shown net of a derivative debt discount of $46,293 at May 31, 2016. (See Note 4 –Convertible Debt).
BioPower
Operations Corporation and Subsidiaries
Notes
to Consolidated Financial Statements
May
31, 2016 and 2015
Unaudited
Since
equity classification is not available for the conversion feature, we were required to bifurcate the embedded conversion feature
and carry it as a derivative liability, at fair value. Derivative financial instrument is carried initially and subsequently at
its fair values.
We
estimated the fair value of the derivative on the inception date, and subsequently, using the Black-Scholes valuation technique,
adjusted for the effect of dilution, because that technique embodies all of the assumptions (including, volatility, expected terms,
and risk free rates) that are necessary to fair value complex derivate instruments.
As
a result of the application of ASC No. 815 in period ended May 31, 2016 the fair value of the conversion feature is summarized
as follows:
|
|
Amount
|
|
Balance November 30, 2015
|
|
$
|
-
|
|
Debt discount originated from derivative liabilities
|
|
|
47,132
|
|
Change in fair market value of derivative liabilities
|
|
|
(18
|
)
|
Balance May 31, 2016
|
|
$
|
47,114
|
|
The
fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following
management assumptions as of May 31, 2016 and commitment date:
|
|
Commitment Date
|
|
|
May 31, 2016
|
|
Expected dividends
|
|
|
-
|
|
|
|
-
|
|
Expected volatility
|
|
|
268.40
|
%
|
|
|
270.72
|
%
|
Expect term
|
|
|
2.00
|
|
|
|
1.96
|
|
Risk free interest rate
|
|
|
0.63
|
%
|
|
|
0.68
|
%
|
On
May 23, 2016, the Company entered into a convertible loan agreement with a third party investor. The Company received a total
of $25,000 which bears interest at 8% per annum and is due on May 23, 2018. Interest shall accrue from the advancement date and
shall be payable on May 23, 2018. Any portion of the loan and unpaid interest are convertible at any time at the option of the
lender into shares of common stock of the Company at a conversion price of $0.10 per share. If an equity transaction occurs at
a price below $0.10, then the conversion price will adjust to such price.
On
this date of issuance, the Company recorded a debt discount in the amount of $23,579 in connection with the initial valuation
of the derivative liability of the note to be amortized utilizing the effective interest method of accretion over the term of
the note. Further, the Company recognized a derivative liability of $23,579 resulting in no initial gain or loss on the derivative
liability based on the Black Scholes pricing model. As of May 31, 2016, $258 of the debt discount has been amortized. The fair
value of the derivative liability at May 31, 2016 is $23,579. The Note is shown net of a derivative debt discount of $23,321 at
May 31, 2016. (See Note 4 –Convertible Debt).
Since
equity classification is not available for the conversion feature, we were required to bifurcate the embedded conversion feature
and carry it as a derivative liability, at fair value. Derivative financial instrument is carried initially and subsequently at
its fair values.
We
estimated the fair value of the derivative on the inception date, and subsequently, using the Black-Scholes valuation technique,
adjusted for the effect of dilution, because that technique embodies all of the assumptions (including, volatility, expected terms,
and risk free rates) that are necessary to fair value complex derivate instruments.
BioPower
Operations Corporation and Subsidiaries
Notes
to Consolidated Financial Statements
May
31, 2016 and 2015
Unaudited
As
a result of the application of ASC No. 815 in period ended May 31, 2016 the fair value of the conversion feature is summarized
as follows:
|
|
|
Amount
|
|
Balance November 30, 2015
|
|
$
|
-
|
|
Debt discount originated from derivative liabilities
|
|
|
23,579
|
|
Change in fair market value of derivative liabilities
|
|
|
-
|
|
Balance May 31, 2016
|
|
$
|
23,579
|
|
The
fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following
management assumptions as of May 31, 2016 and commitment date:
|
|
|
Commitment
Date
|
|
|
|
May
31, 2016
|
|
Expected dividends
|
|
|
-
|
|
|
|
-
|
|
Expected volatility
|
|
|
268.94
|
%
|
|
|
270.29
|
%
|
Expect term
|
|
|
2.00
|
|
|
|
1.98
|
|
Risk free interest rate
|
|
|
0.69
|
%
|
|
|
0.68
|
%
|
Note
7. Stockholders’ Deficit
For
the six months ended May 31, 2016:
On
February 24, 2016, the Board of Directors approved the following stock compensation because the Company did not making any cash
payments toward salary during the year ended November 30, 2015. The stock compensation is to be paid by November 30, 2016 provided
the Company has revenues from operations that can provide for the taxes due for the stock compensation, or the stock will be returned
to the Company. The stock will be issued and held by the Transfer Agent until November 30, 2016 and then returned to the Company
or distributed to the employee. The employee has the option to pay the Company for the employer taxes due and their own taxes
due for the stock compensation on or before November 30, 2016.
The
company fair valued these shares as of the date of issuance and recorded $500,000 stock-based compensation during the first quarter
ended February 29, 2016.
Dr.
Neil Williams, CEO G3P
|
2,000,000
|
|
common
stock shares
|
Robert
Kohn, CEO BioPower
|
1,250,000
|
|
common
stock shares
|
Bonnie
Nelson, Director of Strategy
|
1,250,000
|
|
common
stock shares
|
Benjamin
Williams, Sr. Vice President
|
500,000
|
|
common
stock shares
|
Total
|
5,000,000
|
|
common
stock shares
|
On
March 2, 2016, the Company authorized the issuance of 3,000,000 shares of its common stock, as part of Mr. Baruch Halpern’s
Employment contract, to remain in the possession of the Transfer Agent for one year. The 3,000,000 common shares will be released
to Mr. Halpern after one year as long as he does not voluntarily resign. At that time a standard two-year lock-up agreement will
also be executed. If Mr. Halpern voluntarily resigns before his first anniversary, there will be a claw-back of 2,250,000 common
shares and Mr. Halpern will be issued the remaining 750,000 common shares with a two-year lock-up agreement.
There
are 47,107,680 and 42,107,680 shares issued and outstanding at May 31, 2016 and November 30, 2015, respectively.
BioPower
Operations Corporation and Subsidiaries
Notes
to Consolidated Financial Statements
May
31, 2016 and 2015
Unaudited
Note
8. Commitments and Contingencies
Commitments
Employment
Agreements – Officers and Directors
As
of November 30, 2014, the Company had employment agreements with certain officers and directors (two individuals) containing the
following provisions:
Term
of contract
|
|
4
years, expiring on November 30, 2018
|
Salary
|
|
$275,000
commencing December 1, 2014
|
Salary
deferral
|
|
All
salaries will be accrued but may be paid from the Company’s available cash flow funds.
|
Annual
Salaries:
Name
|
|
Starting
Dc. 1, 2014
|
|
|
2014-15
|
|
|
2015-2016
|
|
|
2016-2017
|
|
Robert Kohn
|
|
|
|
|
|
$
|
275,000
|
|
|
$
|
325,000
|
|
|
$
|
375,000
|
|
Bonnie Nelson
|
|
|
|
|
|
$
|
275,000
|
|
|
$
|
325,000
|
|
|
$
|
375,000
|
|
As
of May 20, 2016 the salaries have been amended to $120,000 each per annum until financing for a second project is committed. These
salary levels will be retroactive to December 1, 2014.
On
March 10 , 2016, the Company employed Mr. Baruch Halpern join as its’ Chief Operating Officer containing the following
provisions:
Term
of contract
|
|
2
years and 5 months, expiring on August 10, 2018
|
Salary
|
|
$120,000
commencing March 10, 2016
|
Salary
deferral
|
|
All
salaries will be accrued but may be paid from the Company’s available cash flow funds.
|
The
accrued officers and directors payroll at May 31, 2016 is $377,000.
Lease
Agreement
On
June 3, 2013, the Company entered into a new lease agreement with its current landlord. The lease is for a 24 month period, expiring
on May 31, 2015 , and requires monthly base rental payments of $ 4,000 for the period from June 1, 2013 through May 31, 2014 and
$ 4,080 for the period from June 1, 2014 through May 31, 2015 plus adjustments for Common Area Expenses. On May 29, 2015, the
Company Amended the lease agreement extending it for an additional 12 month period, expiring on May 31, 2016, and requiring monthly
base rental payments of $4,583 plus adjustments for Common Area Expenses. On May 23, 2016, the Company amended the lease agreement
extending it on a month to month basis. The required monthly base rental payments were kept the same.
Rent
expense was $28,210 and $25,425 for the six month period ended May 31, 2016 and May 31, 2015, respectively.
Contingencies
From
time to time, the Company may be involved in legal matters arising in the ordinary course of business. While the Company believes
that such matters are currently not material, there can be no assurance that matters arising in the ordinary course of business
for which the Company is, or could be, involved in litigation, will not have a material adverse effect on its business, financial
condition or results of operations.
Note
9. Subsequent Events
On
May 31, 2016 a third party investor entered into an agreement to loan $200,000 to the Company, due on or before May 31, 2018.
Pursuant to the agreement, the investor is allowed to convert 100% of the debt at a share price of $0.10. The funds were not received
until June, 2016 and accordingly were not accounted for in the current period.